JCR Pharmaceuticals Co., Ltd. (4552) AI Stock Analysis

• Market Cap: ¥79.20B
• Dividend Yield: 3.47%
• Average Volume (3M): 578.69K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.86
• Revenue Growth: 7.15%
• EPS Growth: -454.41%
• Country: JP
• Employees: 934
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 18.51
• Shares Outstanding: 129,686,310
• 10 Day Avg. Volume: 668,090
• 30 Day Avg. Volume: 578,686
• PEG Ratio: 0.07
• Price to Book (P/B): 1.27
• Price to Sales (P/S): 1.81
• P/FCF Ratio: -3.90
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥600.00
• Price Target Upside: 0.33% Upside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 2

• Rating: 45 Neutral
• Price Target: ¥583.00 ▼(-2.51% Downside)

The overall stock score of 45 reflects significant financial challenges, including declining profitability and liquidity constraints. Technical analysis suggests a bearish trend, and the valuation is poor due to negative earnings. The dividend yield is a minor positive, but concerns about sustainability persist. The absence of earnings call data and corporate events limits further insights.

JCR Pharmaceuticals Co., Ltd. Business Overview & Revenue Model

Company Description

JCR Pharmaceuticals Co., Ltd. (4552) is a Japanese biopharmaceutical company focused on the development, manufacturing, and commercialization of innovative therapies, particularly in the fields of rare diseases and regenerative medicine. The company specializes in producing enzyme replacement therapies and other biopharmaceutical products that leverage advanced biotechnological methods. With a strong emphasis on research and development, JCR Pharmaceuticals aims to address unmet medical needs and improve patient outcomes through its core offerings.

How the Company Makes Money

JCR Pharmaceuticals generates revenue primarily through the sale of its biopharmaceutical products, including enzyme replacement therapies for rare diseases, which are often priced at a premium due to their specialized nature. The company also engages in collaborations and partnerships with other pharmaceutical companies and research institutions, which can provide additional revenue through licensing agreements, co-development projects, and milestone payments. Furthermore, government subsidies and grants for research into rare diseases can contribute to its funding, enhancing its financial stability and ability to invest in new product development.

JCR Pharmaceuticals Co., Ltd. Financial Statement Overview

Summary

JCR Pharmaceuticals Co., Ltd. faces significant financial challenges. Declining profitability and revenue, with negative margins, indicate operational inefficiencies. The balance sheet is stable but under pressure from increasing debt levels. Cash flow issues are apparent with negative operating and free cash flows, indicating liquidity constraints. Overall, the company needs to address revenue growth, cost management, and debt levels to improve its financial health.

Income Statement

The income statement reflects significant volatility. Gross profit margins were generally strong in past years but have suffered recently due to declining revenue and increased costs. The net profit margin has turned negative in the latest year, indicating operational challenges. Revenue growth has been inconsistent, with a notable decline in the most recent year. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies.

Balance Sheet

The balance sheet shows a stable equity base, but with a concerning rise in total debt, increasing the debt-to-equity ratio. Return on equity has turned negative due to recent net losses. However, the equity ratio remains healthy, indicating a strong asset base relative to liabilities. The financial structure suggests potential risks if the current trend of increasing debt continues.

Cash Flow

The cash flow statement highlights challenges with a negative free cash flow and operating cash flow in the latest period. The operating cash flow to net income ratio shows poor cash generation from operations, suggesting inefficiencies. The free cash flow has decreased significantly, raising concerns about the company's ability to fund operations and growth without external financing.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	33.50B	33.07B	42.87B	34.34B	51.08B	30.09B
Gross Profit	21.86B	21.55B	31.25B	25.46B	40.62B	22.27B
EBITDA	-4.42B	-2.88B	10.53B	7.45B	21.39B	10.59B
Net Income	-5.50B	-4.76B	5.51B	3.77B	14.51B	6.89B
Balance Sheet
Total Assets	107.34B	104.86B	102.23B	94.94B	97.13B	73.78B
Cash, Cash Equivalents and Short-Term Investments	13.18B	13.20B	18.76B	13.28B	30.98B	26.26B
Total Debt	40.10B	38.10B	23.30B	22.80B	18.10B	18.10B
Total Liabilities	60.72B	57.42B	45.75B	42.52B	46.05B	35.23B
Stockholders Equity	46.26B	47.04B	56.18B	52.16B	50.88B	38.38B
Cash Flow
Free Cash Flow	0.00	-15.37B	7.22B	-14.06B	-2.04B	2.81B
Operating Cash Flow	0.00	-5.49B	9.31B	-5.50B	9.29B	10.34B
Investing Cash Flow	0.00	-9.87B	-2.69B	-15.00B	-3.25B	-3.29B
Financing Cash Flow	0.00	9.74B	-2.03B	1.95B	-2.18B	8.30B

JCR Pharmaceuticals Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 598.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4552, the sentiment is Negative. The current price of 598 is below the 20-day moving average (MA) of 623.20, below the 50-day MA of 624.77, and above the 200-day MA of 548.84, indicating a neutral trend. The MACD of -5.83 indicates Positive momentum. The RSI at 45.58 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4552.

JCR Pharmaceuticals Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4569	―	¥73.96B	7.84	―	3.70%	9.83%	86.18%
4886	―	¥57.64B	12.11	―	2.48%	6.23%	-31.45%
3341	―	$113.19B	52.01	3.89%	0.64%	6.77%	28.06%
4534	―	¥100.32B	17.35	4.88%	2.71%	2.74%	36.86%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4552	―	¥79.20B	―	―	3.47%	7.15%	-454.41%
4565	―	$87.69B	―	-5.01%	―	33.71%	68.32%

JCR Pharmaceuticals Co., Ltd. Corporate Events

JCR Pharmaceuticals Reports Strong Financial Recovery in First Half of FY2025

JCR Pharmaceuticals reported a significant improvement in its financial performance for the six months ending September 30, 2025, with net sales increasing by 28.2% year-on-year. The company achieved a net profit attributable to owners of the parent of 1,710 million yen, a notable turnaround from the previous year’s loss. This positive financial outcome reflects the company’s strengthened market position and operational efficiency, potentially enhancing stakeholder confidence and supporting future growth initiatives.

The most recent analyst rating on (JP:4552) stock is a Hold with a Yen601.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.

JCR Pharmaceuticals’ JR-141 Study: A Promising Update for Hunter Syndrome Treatment

JCR Pharmaceuticals Co., Ltd. is conducting an extension study titled ‘An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in Mucopolysaccharidosis Type II (Hunter Syndrome) Subjects.’ The study aims to assess the prolonged safety and effectiveness of JR-141, a treatment for Mucopolysaccharidosis II, highlighting its significance in providing long-term therapeutic options for patients.

JCR Pharmaceuticals Advances in MPS IIIB Treatment with JR-446 Study

JCR Pharmaceuticals Co., Ltd. is currently conducting an open-label Phase I/II clinical study titled ‘An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB’. The study aims to evaluate the safety and explore the efficacy of JR-446, a drug in development for treating Mucopolysaccharidosis Type IIIB (MPS IIIB), a rare genetic disorder. This study is significant as it addresses a critical need for effective treatments for this condition.